Background Neither the rate of endoscopic remission (ER) in Crohn's disease (CD) after therapy nor its role in patients' prognosis is well defined.
Introduction
The prevalence of Crohn's disease (CD) has been increasing during the last 40 years, particularly in developed countries [1] [2] [3] . It is a chronic inflammatory condition that can affect any location of the intestinal tract and has a great impact on the quality of life [4] [5] [6] . In most series the distal small bowel is the most affected segment, with up to 80% of patients having this involvement, usually in the terminal ileum, followed closely by proximal large bowel that is affected roughly in one-half of these patients [7, 8] .
Although in most intestinal diseases endoscopic healing is the gold standard of treatment, this is not the practice in CD even in clinical trials [9] [10] [11] . Although endoscopic findings are fundamental for the diagnosis of CD, on account of the complexity of involvement and the predilection for the disease to affect distal small bowel, measuring disease activity is mainly carried out with clinical and laboratorial parameters [6] .
Some authors have evaluated endoscopic findings in these patients and some endoscopic activity indices have been used in clinical trials, namely Crohn's Disease Endoscopic Index of Severity (CDEIS) [12] . However, endoscopic response and remission, endoscopic and mucosal healing, or other endoscopic outcomes for CD patients have not been consistently defined among studies [9] . More importantly, though some therapies used in CD are associated with endoscopic changes, the clinical significance of these improvements has not been fully established till now [10, 13] .
The aim of this study is to systematically review published data to find the proportion of endoscopic changes and/or endoscopic healing of the mucosa for the different medical therapies used in CD; and then, to understand whether these endoscopic improvements alter the prognosis of the patients.
Methods
Type of study and search strategy A systematic review was carried out on published articles that assessed endoscopic evaluation of CD patients identified through a literature search of MEDLINE and Cochrane using the following query, optimized by three reviewers: ['Crohn Disease'(MeSH) OR 'Crohn Disease/diet therapy'(MeSH) OR 'Crohn Disease/drug therapy'(MeSH) OR 'Crohn Disease/history'(MeSH) OR 'Crohn Disease/mortality'(MeSH) OR 'Crohn Disease/prevention and control'(MeSH) OR 'Crohn Disease/therapy'(MeSH)] AND ['endoscopic remission (ER)'(All Fields) OR 'mucosal healing'(All Fields) OR 'endoscop*'(All Fields) OR 'endoscopic findings' OR 'histological healing' OR 'histological remission' OR 'colonoscopic healing' OR 'healing']. Next, a comprehensive search of reference lists of all review articles and original papers achieved by this method was performed to identify additional reports that could be included in the final analysis. A total of 482 papers published until January 2008 was identified.
Inclusion and exclusion criteria
Only journal papers were included where patients with CD were studied and evaluated by endoscopy before and after a predetermined therapy and when the results of that evaluation were clearly reported in the article, independent of being primary or secondary outcome.
Studies were excluded if: two or more therapies were evaluated in combination, the evaluation of mucosal improvement was made only with nonendoscopic methods (virtual colonoscopy, radiology or scintigraphy); endoscopic evaluation was made but there were no references to the therapy used (e.g. clinical-endoscopy correlation); only fistulizating disease; only upper digestive or perineal disease; prophylaxis of recurrence; animal models; unconventional therapies when only one study with few patients (less than 10 patients) were evaluated by endoscopy; case reports and information only in abstracts. When the papers were clearly not about CD or clearly did not respect the inclusion criteria, they were excluded. A total of 273 abstracts were read by two reviewers. This left 32 original papers for reading. Additional eight papers were excluded leaving 24 articles for the analysis. Two of the manuscripts reported data from the same population, which was considered only once ( Fig. 1 ).
Data extraction
Each paper was critically reviewed and creation of extraction forms for data was performed. Data abstraction was carried out by two independent reviewers using the full study reports of the potential articles. Differences were solved by consensus.
The following data were extracted: study design; setting; interventions/therapy; total number of patients and number of patients evaluated by endoscopy; demographic and endoscopic (e.g. localization of disease) characteristics of patients; inclusion, and exclusion criteria; definition of endoscopic outcomes (and other outcomes); time for endoscopic reevaluation; clinical, laboratory (when available), and endoscopic results at the time of endoscopic evaluation; correlation between endoscopic changes and prognosis (when available).
As far as endoscopic results are concerned, different parameters were further defined: proportion of improvement as the percentage of decrease in endoscopic scores; proportion of patients in ER, either using the definition considered by authors in each manuscript (or its interpretation) or using a standardized measure proposed by us as the disappearance of ulcers in follow-up endoscopies [meaning in this case mucosal healing (MH)]. When this information was given separately in ileum and colon we calculated a pooled result considering the proportion of the localization of the disease. Time to endoscopic results was considered according to the presented data in manuscript concerning the time elapsed between initial and follow-up endoscopic evaluations. Short-term, mid-term, and long-term evaluation was defined as those occurring at 2-6 weeks; 6-12 weeks; and over 12 weeks, respectively, according to the more frequent time periods for follow-up in majority of studies.
Moreover, quality of manuscripts was addressed by using CONSORT scale for randomized controlled trials or for nonrandomized clinical trials [14] or STROBE scale for observational studies [15] . In each case, a pontuation was defined by the sum of all parameters considered as adequately described in the manuscript (maximum of 40). Furthermore, three categories of high, medium, and low quality were defined as final pontuation was over 30, between 20 and 30, and less than 20 points, respectively. The study details of the papers are summarized in Table 1 .
Statistical analysis
Patients' data and endoscopic scores were summarized according to original data using adequate measures according to the available data: mean (and standard error, based on published standard deviation) or median (with minimum and maximum value).
Pooled results were determined by using fixed models for percentage of improvement and ER (and 95% confidence intervals estimated). w 2 test (with a level of significance of 0.05) was used for the comparison of pooled proportions. Subgroup analysis concerning the comparison among different studies was carried out according to the type of study (experimental vs. observational); quality of manuscripts (high, medium, and low); and time to the endoscopic outcome (short-term, mid-term, and long-term). For short-term, mid-term, and long-term evaluations, results were pooled according to the type of study, taking the quality of studies into account.
Linear regression models weighed for the numbers of patients in each manuscript were assessed for the explanation of the potential relation between clinical remission (CR) by improvement or ER.
Results

Type of studies and endoscopic evaluation
Most (79%) of included studies were clinical trials, eight randomized trials (33%) [11, 13, [16] [17] [18] [19] [20] [21] [22] and 11 nonrandomized (n = 50%) [16, 17, 20, 22, 25, [29] [30] [31] [32] 35, 36] . Five manuscripts were observational [19, 24, 28, 33, 34] . Only three studies compared the effect of the intervention against placebo [21, 37, 38] and none studied the effects of mesalazine in mucosal healing. Adult population was assessed in 17 studies (71%) [11, 16, 17, [20] [21] [22] 26, 27, [31] [32] [33] [34] [35] 37, 38] , children being evaluated in seven studies (29%) [18, 19, 23, 25, [28] [29] [30] . The most common therapy studied for endoscopic evaluation was enteric diet, independent of the type of diet, with seven studies (29%) [18, 19, [27] [28] [29] [30] [31] and infliximab (IFX) also with seven Papers excluded as they clearly didn't respect inclusion criteria (n = 209)
Papers excluded because they were about fistulizating disease/surgery/perineal disease only (n = 89), review articles (n =94), evaluation of mucosal improvement was made only with nonendoscopic methods (n =10), endoscopic evaluation was made but there were no references to the therapy used (n =16), only upper digestive disease (n =11), prophylaxis of recurrence (n =4), animal models (n = 2), ulcerous colitis (n = 6), nonconventional therapies when only one study with few patients were evaluated by endoscopy (n = 2), two or more therapies were used in combination (n = 4) and case reports (n = 3)
Papers excluded because only histological data provided (n =1), the same population was used again in other study (n = 2), only fistulizating disease (n = 1), endoscopic data not clear (n =3), nonconventional therapy with only one study with few patients were evaluated by endoscopy (n = 1)
Potentially appropriate papers to be included in systematic review (n = 32)
Potentially relevant papers identified on MEDLINE and through explosion of references (n = 482)
Abstracts of papers analysed for relevance (n =273)
Papers used for analysis (n = 24)
Flow diagram indicating the criteria for analyzing papers in this review.
Endoscopic remission in Crohn's disease Pimentel-Nunes et al. 493 studies (29%) [20] [21] [22] [23] 25, 26] . Five studies evaluated the effect of steroids [11, [16] [17] [18] [19] in mucosal improvement; two of them were randomized controlled trial (RCT) [11, 18] . However, none compared steroids against placebo. Azathioprine was evaluated in three studies, two of them observational and in the majority of patients the induction of remission was also with steroids (steroids resistance or dependence) despite the fact that most of the patients were steroid-free at the time of the second endoscopic evaluation [32] [33] [34] . Until January 2008 we did not find any study with adalimumab or certolizumab that respected inclusion criteria.
Across the 24 studies selected, 10 different methods for endoscopic evaluation were used, with CDEIS being the most used endoscopic score (38%) [11, 13, 17, 18, 21, 25, [36] [37] [38] . A score of severity from 0 (no lesions) to 3 (very severe disease) was also common, being used in 17% of the studies [19, [29] [30] [31] . All the other studies (45%) used uncommon scores or descriptions of the severity of the lesions with subjective scales of improvement.
Only five studies considered previous surgery (21%) as exclusion criteria [19, 21, 27, 31, 37] . However, only two studies evaluated the efficacy of therapy in a population constituted only by postsurgery recurrence [16, 33] . When considering the localization of the disease only six (25%) evaluated ileum and colon separately [16, 18, 21, 29, 31, 34] .
In Table 1 we can see the description of studies.
Endoscopic remission
No definition for ER was given by authors in 12 (50%) of the studies [16, [21] [22] [23] 25, 27, 28, 30, [35] [36] [37] [38] . However, in six of these we were able to consider ER using data included in the paper (e.g. markedly improved; complete improvement; no ulcerations) [16, 22, 27, 28, 35, 37] . The definition of ER was not the same among the studies with some authors considering only the normal appearance of mucosa (e.g. score equal to 0 when used the 3 grade score) and others accepting minor lesions or scared lesion (Table 1) . Although CDEIS was the most used score, only two studies defined remission based on the change of CDEIS (e.g. inflammatory remission when Z 50% decrease in both CDEIS and histological score) [18, 25] . [19] using the 0-3 severity scale obtained a less-pronounced reduction (29%) in score (n = 10). Considering ER using authors' criteria (ER as CDEIS improvement Z 50%, minor lesions to normal mucosa) corticosteroids were associated with 27% of ER (95% CI: 21-33%; n = 222) after 4-12 weeks of treatment.
Infliximab
If we consider all the studies that used CDEIS for endoscopic evaluation, independent of posology, we obtained a reduction of CDEIS of 70% (95% CI: 62-78%; n = 121 patients) at 4-54 weeks follow-up. Four weeks after a single infusion of IFX and using a 0-10 score of severity, Baldassano et al. [23] showed a 52% of reduction in score (n = 9). Rutgeerts et al. [13] showed that maintenance of IFX therapy for 54 weeks was associated with 93% improvement in CDEIS (n = 36).
Considering ER as markedly endoscopic improvement to complete endoscopic healing (normal appearance) we obtain an ER of 47% (95% CI: 39-55%; n = 136) after 4-54 weeks of treatment with IFX.
Enteric diets
When the most common endoscopic score is applied for evaluation of the effect of enteric diets (0-3 score of severity) we obtain an improvement of 63% (95% CI: 53-72%; n = 91) after 4-10 weeks of therapy. Borrelli et al. [18] used Considered only the patients with CR but not ER that were reevaluated (Group B of this study). c Remission was defined according to authors' criteria (see Table 1 ), or when not defined, as no ulcerations (when possible). CDEIS and obtained a significant and similar improvement in score (54%). Using authors' criteria for ER, that generally were more restricted than those used for steroids, ER was obtained after 4-10 weeks of treatment in 36% of patients (95% CI: 28-44%; n = 137).
Immunomodulators
As previously said, the effects of azathioprine in MH/ER were only evaluated in three studies, none of these was RCT and only one was a controlled trial. Nevertheless, azathioprine was associated with 54% of ER (95% CI: 38-69%; n = 41) after a mean time of therapy of 19 months.
Kozarek et al. [35] showed that methotrexate 25 mg/w for 12 weeks was associated with 35.7% of ER; however, only 14 patients were studied.
Other therapies
The results from other therapy are shown in Table 2d . As expected all the studies that compared the intervention against placebo showed 0% of ER for placebo. Nevertheless, placebo was associated with a mean improvement in CDEIS of 12% (95% CI: 1-22%; n = 32) (Table 2e ).
Comparison between therapies
Globally, when we compare the pooled proportion of improvement in scores, independent of the score used and according to the therapy, including placebo, we observe that corticosteroids are associated with a mean improvement of 45% (95% CI: 39-52%; n = 214) against 12% (95% CI: 1-22%; n = 37) of placebo (P = 0.0008). In contrast, enteric diets are associated with 61% (95% CI: 52-70%; n = 108) of improvement and IFX with 70% (95% CI: 62-78%; n = 130) against 45% with corticosteroids (P = 0.01 and P < 0.0001, respectively). No statistical difference between enteric diets and IFX is observed (P = 0.19). These results are illustrated in Fig. 2 .
When we examine the proportion of ER, using data only from the articles that give the proportion of no ulcerations (Fig. 3) ,
we observe that corticosteroids are associated with 17% of ER (95% CI: 12-22%; n = 212) and that this result is statistically different from placebo (P = 0.02). Comparing with cortico steroids, the 43% (95% CI: 33-52%; n = 100) of ER obtained with enteric diets is twice as much as the 44% (95% CI: 35-53%; n = 107) obtained with IFX (P < 0.0001). No differences between IFX and diet are observed (P = 0.99). Relation between endoscopic remission (ER) and clinical remission in different studies with steroids, diet, or infliximab (IFX) that considered ER as no ulcerations. For short-term evaluation, the proportion of ER (no ulcers) after a single infusion of IFX was 69% (95% CI: 51-87%; n = 26) significantly higher than 12% (95% CI: 7-17%; n = 139) with daily steroids (P < 0.0001) or 32% (95% CI: 19-45%; n = 52) with enteric diets (P = 0.004) for 4 weeks. ER induced by enteric diets was significantly higher than that induced by steroids (P = 0.003) ( Fig. 4 ). However, one of the studies that evaluate IFX at short term was observational [38] and the other was of low quality [20] , unlike from the studies with steroids (high-quality RCT [17] ) and diets (medium-quality controlled trial [31] and highquality RCT [27] ).
As far as mid-term evaluation is concerned, data only from clinical trials with similar quality, induction with IFX, and evaluation at 10 weeks (single study) [13] after initial infusion was associated with 29% (95% CI: 16-42%; n = 45) of ER, against 27% (95% CI: 16-38%; n = 65) with daily steroids for a mean time of 10 weeks (P = 0.99) and 53% (95% CI: 38-67%; n = 48) with enteric diets for a mean time of 9 weeks (P = 0.03 vs. IFX and P = 0.009 vs. steroids) ( Fig. 4) .
Only five studies evaluated endoscopic outcomes (azathioprine n = 3, IFX n = 1, methotrexate n = 1) at long term; however, they had different evaluation times, different types, and quality of studies and sustainable comparison was not possible.
Prognostic value of endoscopic remission
Only one study tried to access direct correlation of ER with patients' prognosis. In the endoscopic substudy of ACCENT I [13, 26] the authors showed that at 54 weeks 67% of the patients with ER were also in CR against 56% of the patients without ER. They also showed that the number of hospitalizations in 1 year because of relapse of disease was lower in patients with ER at both visits (0%) than ER in only one visit (18.8%) or either visit (28%). However, despite showing a clear trend, these results were not statistically significant (NS).
Modigliani et al. [17] showed that ER was associated with higher values of hemoglobin (13.3 vs. 12.6 g/dl-P < 0.05), less erythrocyte sedimentation rate (13.0 vs. 22-P < 0.01) and potentially less clinical activity (Crohn's disease activity index 65 vs. 79-NS), and higher values of albumin (3.7 vs. 3.5 g/dl-NS), indirect markers of clinical improvement.
Finally, Landi et al. [11] showed that patients with ER could be successfully weaned from steroids in 92% of cases compared with 80% of cases in patients without ER (NS); however, these results did not achieve statistical meaning.
We did not find any linear relation between ER (considering those patients with no ulcerations) and CR. However, when we consider only those studies assessing IFX a positive linear relation (r 2 = 0.931) was found ( Fig. 5 ). Correlation between endoscopic improvement and CR (Fig. 6 ) regarding steroids and diet may be explained by a linear model (r 2 = 0.542 and = 0.968, respectively).
Discussion
We found a great heterogeneity of endoscopic scores for evaluation of the efficacy of several drugs. CDEIS is a prospectively validated endoscopic score [12] being increasingly used; nevertheless, other scores have been used [9] . However, more important than the score applied, is the fact that ER is not a common primary or secondary outcome in clinical trials for CD therapy [9] , and endoscopic evaluation is different between studies.
Several considerations can be made about this study.
Endoscopic improvement can be induced by some therapeutic options, namely biologic therapy (IFX with a mean improvement of 70%) and enteric diets (mean improvement of 61%). Even corticosteroids were associated with significant improvement with a mean reduction in endoscopic lesions of 45%. When ER or MH is considered it is very difficult to compare the different strategies and even draw a straight conclusion about a specific treatment, because till now the concept is heterogeneous and not universally defined. In this study ER is defined as no ulcerations because it was the more common definition or the more easily obtained data. Using this criterion it seems that enteric diets, with 43% of ER, and IFX with 44% of ER, among the therapy available for Crohn's disease, are more probably related to mucosal healing. In this study corticosteroids were associated with 17% of ER, in contrast to the common knowledge that corticosteroids do not promote healing of the mucosa [10, 39] . This result is statistically superior to placebo but clearly lower than that achieved by IFX and enteric diets. Despite 54% of ER induced by azathioprine, this evidence is weak because data came from only three studies neither one of high evidence [32] [33] [34] . Moreover, as postulated by D'Haens et al. [34] , we cannot exclude that steroids may act as inducers of healing in the patients treated with azathioprine, because in most of the studies the majority of patients were taking steroids in the induction phase. However, it seems that azathioprine is effective in achieving or maintaining ER after a long period of time.
In this review we decided to include postsurgery cases when they respected the inclusion criteria. In fact only five studies considered previous surgery (21%) as exclusion criteria [19, 21, 27, 31, 37] . Thus, 19 studies include postsurgery cases. To the best of our knowledge, there is no published study that shows that the mucosal effects from therapy will be different in postsurgery cases. In fact, in the majority of studies analyzed there were no differences reported by authors between surgery and nonsurgery patients.
In contrast, we decided not to include data published only on abstracts because we were not able to ascertain whether they respected inclusion or exclusion criteria in all abstracts that we read at a preliminary reading. Moreover, the data included in some abstracts that could potentially be published were afterwards described as full papers. In our opinion this decision improved the quality of reporting.
Besides methodological considerations and potential heterogeneity regarding patients' characteristics [age (pediatric vs. adults), localization, and severity of disease] among different studies, one of the major limitations of our study is the fact that we are comparing several therapies evaluated by different endoscopic scores, to assess endoscopic endpoints within different time intervals. As suggested by several studies [12, 17, 39] it was not possible to find any correlation between ER and CR when both are evaluated at the same time. However, we found a strong correlation between endoscopic improvement and CR, particularly for enteric diets and corticosteroids. It was very interesting to note that IFX did not achieve this relation when considering endoscopic improvement as the predictive variable, but if we define no ulcerations at follow-up as an endpoint, there was a linear relation with CR. This may be explained by the fact that IFX has not been used as the first-line treatment at present. The patients enrolled in IFX trials have been submitted to several treatments before IFX, most of them being refractory to corticosteroids, azathioprine, and methotrexate [40, 41] . We hypothesized that these more complicated patients may only be in CR when ER is obtained.
Furthermore, probably because of scarce data, no definite conclusions can be drawn from subgroup analysis concerning time to outcome, type, and quality of studies.
Some studies suggest that mucosal inflammation in Crohn's disease is associated with more risk of relapse [42, 43] , and Rutgeerts et al. [44] showed that the presence of postsurgery lesions are associated with bad prognosis. It makes sense that mild inflammation or no inflammation will be associated with less relapse, better quality of life, less progression to neoplasia and in children more growth, although in this review we did not find evidence to support or deny these lines of thought. In fact only one study tried to assess direct correlation between ER and patients' prognosis and this is a major drawback in trials about CD. However, the little data available showed some tendency to change the natural history of CD [10, 13, 29, 39, 45] , allowing us to pursue ER as a goal. We must bear in mind that CD is a transmural inflammation and that is missing a score to wall involvement. However, to follow for a transmural index we need to know what really is endoscopic healing and its clinical value.
To conclude we can say that: first, ER is not precisely defined in the literature; second, we have evidence that some available therapies are able to induce mucosal healing; third, endoscopic improvement may be associated with better prognosis.
Should endoscopic healing be a goal? If so, what is the appropriate timing for that evaluation? We strongly need to define precise endoscopic outcomes and these outcomes should be routinely assessed in clinically randomized prospective trials answer to these questions and to support ER as a gold standard of CD treatment.
